Earnings Feed
Start Free
NEOGENOMICS INC·4

May 5, 4:27 PM ET

Aunan Greg D 4

4 · NEOGENOMICS INC · Filed May 5, 2026

Research Summary

AI-generated summary of this filing

Updated

NeoGenomics (NEO) CAO Greg Aunan Exercises/Receives Shares

What Happened

Greg D. Aunan, Chief Accounting Officer of NeoGenomics, had restricted-equity activity tied to recent vesting/conversion. The filing shows a conversion/exercise event on May 2, 2026 that resulted in 5,372 shares being acquired (reported at $0). In connection with vesting/issuance, the company withheld shares to cover tax obligations: 937 shares on May 1, 2026 and 1,309 shares on May 2, 2026 (both reported as dispositions at $0). The filing also records a same‑date derivative disposition of 5,372 shares (see Key Details/footnotes).

All reported transactions show $0 amounts, consistent with internal conversion/withholding settlements rather than open‑market cash purchases or sales.

Key Details

  • Transaction dates: May 1, 2026 (937 shares withheld), May 2, 2026 (5,372 shares exercised/converted; 1,309 shares withheld; 5,372‑share derivative disposition recorded).
  • Prices/values: All entries reported at $0 (no cash amount shown in the filing).
  • Tax withholding: Total of 2,246 shares (937 + 1,309) surrendered to NeoGenomics to satisfy tax withholding related to RSU/share issuance (footnotes F1, F4).
  • Related grants and vesting: Footnotes indicate multiple prior grants of RSUs and options (e.g., RSUs granted Feb 21, 2025 and Mar 1, 2026; options granted Mar 1, 2026 and earlier) and that the transactions reflect release/vesting of previously reported RSUs (F2, F3, F10–F12).
  • Filing timeliness: No late‑filing flag indicated in the provided summary.
  • Shares owned after transaction: Not specified in the summary provided.

Context

  • Transaction codes: M = exercise/conversion of a derivative (options/RSUs); F = shares surrendered/withheld for tax obligations. The activity appears to be routine vesting/conversion with company withholding to satisfy taxes (not an open‑market sale or discretionary cash purchase).
  • For retail investors: Purchases are generally more informative about insider sentiment; this filing mostly reflects routine vesting/settlement and tax withholding rather than a market purchase or a voluntary large sale.

Insider Transaction Report

Form 4
Period: 2026-05-01
NEOGENOMICS INCNEO
Aunan Greg D
Chief Accounting Officer
Transactions
  • Tax Payment

    Common Stock

    [F1]
    2026-05-01−937→ 21,090 total
  • Exercise/Conversion

    Common Stock

    [F2][F3]
    2026-05-02+5,372→ 26,462 total
  • Tax Payment

    Common Stock

    [F4]
    2026-05-02−1,309→ 25,153 total
  • Exercise/Conversion

    Restricted Stock Unit

    [F5][F6]
    2026-05-02−5,372→ 10,745 total
    Exercise: $0.00→ Common Stock (5,372 underlying)
Holdings

  • Stock Option (Right to Buy)

    [F7]
    Exercise: $14.62Exp: 2030-05-01→ Common Stock (28,662 underlying)
    28,662

  • Stock Option (Right to Buy)

    [F8]
    Exercise: $13.96Exp: 2034-05-02→ Common Stock (26,978 underlying)
    26,978

  • Stock Option (Right to Buy)

    [F9]
    Exercise: $11.86Exp: 2035-02-21→ Common Stock (31,163 underlying)
    31,163

  • Restricted Stock Unit

    [F10][F6]
    Exercise: $0.00→ Common Stock (12,648 underlying)
    12,648

  • Stock Option (Right to Buy)

    [F11]
    Exercise: $9.83Exp: 2036-03-01→ Common Stock (36,825 underlying)
    36,825

  • Restricted Stock Unit

    [F12][F6]
    Exercise: $0.00→ Common Stock (22,889 underlying)
    22,889
Footnotes (12)
  • [F1]Shares surrendered to NeoGenomics, Inc. for retirement to satisfy tax obligations in connection with the May 1, 2026 vesting of restricted stock.
  • [F10]On February 21, 2025, Mr. Aunan was granted 18,971 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F11]On March 1, 2026, Mr. Aunan was granted 36,825 stock options. The options vest ratably over the first three anniversary dates of the grant date.
  • [F12]On March 1, 2026, Mr. Aunan was granted 22,889 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F2]Reflects the release of restricted stock units that were previously reported on a Form 4.
  • [F3]Each restricted stock unit is economic equivalent of one share of NeoGenomics, Inc. common stock and is converted into common stock upon vesting.
  • [F4]Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
  • [F5]On May 2, 2024, Mr. Aunan was granted 16,117 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
  • [F6]Once vested, the shares of common stock are not subject to expiration.
  • [F7]On May 1, 2023, Mr. Aunan was granted 28,662 stock options. The options vest ratably over the first four anniversary dates of the grant date.
  • [F8]On May 2, 2024, Mr. Aunan was granted 26,978 stock options. The options vest ratably over the first three anniversary dates of the grant date.
  • [F9]On February 21, 2025, Mr. Aunan was granted 31,163 stock options. The options vest ratably over the first three anniversary dates of the grant date.
Signature
/s/ Ali Olivo, Attorney-in-Fact|2026-05-05

Documents

1 file
  • 4
    wk-form4_1778012858.xmlPrimary

    FORM 4